Forsta AP Fonden Sells 19,800 Shares of Catalent, Inc. (NYSE:CTLT)

Forsta AP Fonden reduced its position in shares of Catalent, Inc. (NYSE:CTLT) by 52.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,900 shares of the company’s stock after selling 19,800 shares during the period. Forsta AP Fonden’s holdings in Catalent were worth $1,007,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Lindbrook Capital LLC boosted its holdings in shares of Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after acquiring an additional 208 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Catalent in the second quarter worth $42,000. Mather Group LLC. bought a new stake in shares of Catalent during the first quarter worth $52,000. Longfellow Investment Management Co. LLC grew its holdings in shares of Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after purchasing an additional 305 shares during the last quarter. Finally, Principal Securities Inc. acquired a new stake in shares of Catalent in the fourth quarter valued at $56,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CTLT. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, July 11th. William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Barclays lifted their target price on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, June 28th. Finally, StockNews.com began coverage on Catalent in a research note on Tuesday, September 10th. They set a “sell” rating on the stock. One analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, Catalent presently has an average rating of “Hold” and an average target price of $58.08.

Catalent Stock Performance

Shares of Catalent stock opened at $60.16 on Tuesday. Catalent, Inc. has a 52 week low of $31.80 and a 52 week high of $61.20. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.77 and a current ratio of 2.52. The stock has a market capitalization of $10.92 billion, a price-to-earnings ratio of -9.86, a PEG ratio of 1.88 and a beta of 1.15. The firm has a fifty day moving average of $59.27 and a two-hundred day moving average of $57.13.

Insider Activity at Catalent

In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the firm’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the transaction, the chief executive officer now owns 177,521 shares in the company, valued at $10,431,133.96. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the transaction, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Ricky Hopson sold 662 shares of the business’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the completion of the transaction, the insider now directly owns 29,974 shares of the company’s stock, valued at approximately $1,785,251.44. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,409 shares of company stock worth $782,923. 0.31% of the stock is owned by insiders.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.